Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4015440 | 0.82 | CYP17A1 (0.34) | SLC6A4SLC6A2SLC6A3HTR2C | |
| SCHEMBL9291204 | 0.82 | MAOA (0.36) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4021110 | 0.78 | HTR2A (0.35) | HTR6SLC6A4SLC6A2SLC6A3HTR2C | |
| SCHEMBL4023118 | 0.74 | SLC6A2 (0.36) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4023684 | 0.74 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3HTR2C | |
| SCHEMBL4017117 | 0.74 | HTR2C (0.33) | HTR2C | |
| SCHEMBL5817755 | 0.72 | NISCH (0.35) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4111663 | 0.71 | SLC6A4 (0.37) | SLC6A4SLC6A2SLC6A3HTR2C | |
| SCHEMBL14415614 | 0.69 | SLC6A2 (0.52) | HTR6SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3666428 | 0.69 | TAAR1 (0.44) | HTR6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227469-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20090197879-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | BALAN CHENERA | 2009-08-06 | — | — | US | disclosed |
| US-7534798-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20050182067-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197879-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV2, TRPV3 | HTR6 133/4885SLC6A4 691/4885SLC6A2 910/4885 |
| US-20050182067-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | HTR6 133/4885SLC6A4 691/4885SLC6A2 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.